Analyst Coverage Initiated Stock
Report Date: 02-20-2024
Symbol: DYN - Dyne Therapeutics, Inc.
Sector: Utilities
Industry: Biotechnology
Analyst Coverage Initiated: DYN rating Buy by H.C. Wainwright
Price Target: $36
Dyne Therapeutics, Inc. (DYN)
830 Winter Street
Waltham, MA 02451
Phone: 781 786 8230
Website: http://www.dyne-tx.com
CEO: None
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.